LIWANLI Innovation Co., Ltd. (3054.TW)
TWD 23.5
(1.29%)
TWD 23.5
(1.29%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 15.08 Million TWD | 32.39% |
| 2022 | 11.39 Million TWD | 51.08% |
| 2021 | 7.54 Million TWD | 130.03% |
| 2020 | -25.11 Million TWD | -1094.93% |
| 2019 | 2.52 Million TWD | -77.9% |
| 2018 | 11.42 Million TWD | 122.2% |
| 2017 | -51.44 Million TWD | -235.26% |
| 2016 | 38.03 Million TWD | 1269.11% |
| 2015 | 2.77 Million TWD | -97.75% |
| 2014 | 123.21 Million TWD | -68.64% |
| 2013 | 392.88 Million TWD | 607.86% |
| 2012 | 55.5 Million TWD | -34.92% |
| 2011 | 85.28 Million TWD | 127.37% |
| 2010 | 37.5 Million TWD | -74.11% |
| 2009 | 144.87 Million TWD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 4.46 Million TWD | 28.6% |
| 2024 Q2 | 3.46 Million TWD | -55.77% |
| 2024 Q1 | 7.84 Million TWD | 128.93% |
| 2023 Q3 | 2.66 Million TWD | -51.61% |
| 2023 Q2 | 5.5 Million TWD | 58.21% |
| 2023 Q1 | 3.48 Million TWD | 40.12% |
| 2023 FY | 15.08 Million TWD | 32.39% |
| 2023 Q4 | 3.42 Million TWD | 28.51% |
| 2022 Q2 | 2.98 Million TWD | 0.85% |
| 2022 FY | 11.39 Million TWD | 51.08% |
| 2022 Q4 | 2.48 Million TWD | -16.3% |
| 2022 Q1 | 2.95 Million TWD | -10.2% |
| 2022 Q3 | 2.96 Million TWD | -0.44% |
| 2021 FY | 7.54 Million TWD | 130.03% |
| 2021 Q1 | -3.14 Million TWD | 81.3% |
| 2021 Q2 | 4.81 Million TWD | 253.28% |
| 2021 Q3 | 2.57 Million TWD | -46.61% |
| 2021 Q4 | 3.29 Million TWD | 27.98% |
| 2020 Q2 | -628 Thousand TWD | 75.13% |
| 2020 Q1 | -2.52 Million TWD | -34.95% |
| 2020 FY | -25.11 Million TWD | -1094.93% |
| 2020 Q4 | -16.81 Million TWD | -226.89% |
| 2020 Q3 | -5.14 Million TWD | -719.11% |
| 2019 FY | 2.52 Million TWD | -77.9% |
| 2019 Q2 | 1.03 Million TWD | -62.73% |
| 2019 Q3 | 594 Thousand TWD | -42.44% |
| 2019 Q1 | 2.76 Million TWD | -20.43% |
| 2019 Q4 | -1.87 Million TWD | -414.98% |
| 2018 Q3 | 2.23 Million TWD | -63.82% |
| 2018 Q2 | 6.16 Million TWD | 1449.45% |
| 2018 Q4 | 3.48 Million TWD | 55.98% |
| 2018 FY | 11.42 Million TWD | 122.2% |
| 2018 Q1 | -457 Thousand TWD | 98.86% |
| 2017 Q4 | -40.13 Million TWD | -191.57% |
| 2017 Q1 | 13.1 Million TWD | -44.42% |
| 2017 Q2 | -10.64 Million TWD | -181.27% |
| 2017 Q3 | -13.76 Million TWD | -29.29% |
| 2017 FY | -51.44 Million TWD | -235.26% |
| 2016 Q4 | 23.56 Million TWD | 439.81% |
| 2016 Q1 | 6.25 Million TWD | 154.18% |
| 2016 FY | 38.03 Million TWD | 1269.11% |
| 2016 Q2 | 3.84 Million TWD | -38.55% |
| 2016 Q3 | 4.36 Million TWD | 13.58% |
| 2015 Q1 | 12.82 Million TWD | 371.78% |
| 2015 FY | 2.77 Million TWD | -97.75% |
| 2015 Q4 | -11.54 Million TWD | -120.51% |
| 2015 Q3 | -5.23 Million TWD | -177.69% |
| 2015 Q2 | 6.74 Million TWD | -47.43% |
| 2014 Q4 | -4.71 Million TWD | -123.62% |
| 2014 FY | 123.21 Million TWD | -68.64% |
| 2014 Q1 | 58.88 Million TWD | -19.08% |
| 2014 Q2 | 49.07 Million TWD | -16.66% |
| 2014 Q3 | 19.97 Million TWD | -59.3% |
| 2013 Q4 | 72.77 Million TWD | 15.53% |
| 2013 FY | 392.88 Million TWD | 607.86% |
| 2013 Q1 | 128.64 Million TWD | 639.15% |
| 2013 Q2 | 128.48 Million TWD | -0.12% |
| 2013 Q3 | 62.99 Million TWD | -50.97% |
| 2012 Q3 | -27.51 Million TWD | -194.45% |
| 2012 Q1 | 31.76 Million TWD | -19.34% |
| 2012 FY | 55.5 Million TWD | -34.92% |
| 2012 Q4 | 17.4 Million TWD | 163.25% |
| 2012 Q2 | 29.13 Million TWD | -8.29% |
| 2011 Q2 | -14.26 Million TWD | -152.55% |
| 2011 Q3 | 33.01 Million TWD | 331.37% |
| 2011 Q4 | 39.38 Million TWD | 19.31% |
| 2011 FY | 85.28 Million TWD | 127.37% |
| 2011 Q1 | 27.15 Million TWD | 139.85% |
| 2010 Q2 | -482 Thousand TWD | -101.62% |
| 2010 FY | 37.5 Million TWD | -74.11% |
| 2010 Q3 | -3.02 Million TWD | -526.76% |
| 2010 Q1 | 29.69 Million TWD | 0.0% |
| 2010 Q4 | 11.32 Million TWD | 474.74% |
| 2009 FY | 144.87 Million TWD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Grape King Bio Ltd | 8.53 Billion TWD | 99.823% |
| Standard Chem & Pharm CO., LTD. | 2.72 Billion TWD | 99.447% |
| Maywufa Company Ltd. | 854.37 Million TWD | 98.235% |
| ScinoPharm Taiwan, Ltd. | 1.21 Billion TWD | 98.76% |
| Lotus Pharmaceutical Co., Ltd. | 8.33 Billion TWD | 99.819% |
| YungShin Global Holding Corporation | 2.91 Billion TWD | 99.482% |
| PhytoHealth Corporation | 67.64 Million TWD | 77.702% |
| SCI Pharmtech, Inc. | 350.32 Million TWD | 95.695% |
| Formosa Laboratories, Inc. | 1.9 Billion TWD | 99.208% |
| PharmaEssentia Corporation | 4.49 Billion TWD | 99.664% |
| Bora Pharmaceuticals Co., LTD. | 6.99 Billion TWD | 99.784% |